LY3372689

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3372689, covering 2025-07-28 to 2025-07-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease [Phase 2]

See pricing